Peptide-based imaging agents for cancer detection.
Peptide-based imaging agents for cancer detection.
复制标题
用于癌症检测的基于肽的成像剂
DOI：
10.1016/j.addr.2016.06.007
复制
发表时间：
2017-02
影响因子：
16.1
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Sun X;Li Y;Liu T;Li Z;Zhang X;Chen X
基于选择性受体靶向肽的试剂在过表达相应肽受体的肿瘤细胞的分子成像中引起了相当大的关注，这是由于其独特的性质，例如从循环中快速清除以及对其靶标的高亲和力和特异性。化学修饰技术的快速发展使得各种基于肽的成像剂的设计和开发成为可能，这些成像剂具有增强的代谢稳定性、有利的药代动力学、改善的结合亲和力和选择性、更好的成像能力以及生物安全性。其中，许多放射性标记的肽已经被转化为临床，具有令人印象深刻的诊断准确性和灵敏度。本文综述了肽类显像剂的研究现状，重点介绍了肽类显像剂探针设计的几个方面，包括肽的筛选、探针的化学修饰以及临床应用的标准。与其他FDA批准的显像剂相比，还提供了临床试验中的具体实例。
Selective receptor-targeting peptide based agents have attracted considerable attention in molecular imaging of tumor cells that overexpress corresponding peptide receptors due to their unique properties such as rapid clearance from circulation as well as high affinities and specificities for their targets. The rapid growth of chemistry modification techniques has enabled the design and development of various peptide-based imaging agents with enhanced metabolic stability, favorable pharmacokinetics, improved binding affinity and selectivity, better imaging ability as well as biosafety. Among them, many radiolabeled peptides have already been translated into the clinic with impressive diagnostic accuracy and sensitivity. This review summarizes the current status in the development of peptide-based imaging agents with an emphasis on the consideration of probe design including the identification of suitable peptides, the chemical modification of probes and the criteria for clinical translation. Specific examples in clinical trials have been provided as well with respect to their diagnostic capability compared with other FDA approved imaging agents.
DOI：
10.2967/jnumed.110.079418
发表时间：
2010-11
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Jacobson O;Weiss ID;Kiesewetter DO;Farber JM;Chen X
通讯作者：
Chen X